J.P. Morgan Keeps Their Hold Rating on Morphosys Ag (MOR)

In a report released on August 9, James Gordon from J.P. Morgan maintained a Hold rating on Morphosys Ag (MORResearch Report), with a price target of $8.30. The company’s shares closed yesterday at $5.79.

According to TipRanks, Gordon is ranked #3245 out of 7954 analysts.

Morphosys Ag has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.

See today’s best-performing stocks on TipRanks >>

MOR market cap is currently $786.8M and has a P/E ratio of -0.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Read More on MOR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More